XML 56 R4.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Net revenues $ 4,264 $ 4,529 $ 12,896 $ 14,295
Cost of sales 2,435 2,552 7,318 7,970
Gross profit 1,830 1,977 5,579 6,325
Research and development expenses 240 311 778 918
Selling and marketing expenses 595 699 1,908 2,119
General and administrative expenses 285 309 873 954
Intangible assets impairment 177 519 1,206 1,246
Goodwill impairment       300
Other assets impairments, restructuring and other items 160 139 263 834
Legal settlements and loss contingencies 468 19 1,171 (1,239)
Other income (14) (35) (29) (334)
Operating income (loss) (81) 16 (591) 1,527
Financial expenses, net 211 229 635 736
Income (loss) before income taxes (292) (213) (1,226) 791
Income taxes (benefit) 11 (26) (159) (56)
Share in losses of associated companies, net 4 10 8 76
Net income (loss) (307) (197) (1,076) 771
Net income attributable to non-controlling interests 7 11 33 35
Net income (loss) attributable to Teva (314) (208) (1,108) 736
Dividends on preferred shares   65   195
Net income (loss) attributable to ordinary shareholders $ (314) $ (273) $ (1,108) $ 541
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ (0.29) $ (0.27) $ (1.02) $ 0.53
Diluted $ (0.29) $ (0.27) $ (1.02) $ 0.53
Weighted average number of shares (in millions):        
Basic 1,092 1,018 1,091 1,018
Diluted 1,092 1,018 1,091 1,020